NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Sep 30, 2024. Filed Dec 17, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 17, 2024
NMTC$0.89+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Years ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(12,318,110) | $(11,859,491) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization and depreciation | 246,791 | 199,266 |
| Amortization of deferred issuance costs | 101,329 | — |
| Stock-based compensation | 1,344,476 | 1,105,457 |
| Fair value change in warrant liability | 327,092 | — |
| Private placement warrant issuance costs reclassed to financing activities | 127,659 | — |
| Loss on disposal of fixed assets | — | 32,143 |
| Amortization of discounts and premiums on short-term investments | — | (45,571) |
| Non-cash lease expense | 113,534 | 109,832 |
| Change in assets and liabilities: | ||
| Accounts receivable | (176,636) | 33,237 |
| Inventory | (908,467) | (1,022,148) |
| Prepaid expenses | 47,285 | 32,903 |
| Accounts payable | 66,993 | (247,189) |
| Accrued expenses, deferred revenue, operating lease and other liabilities | 16,214 | (1,225,313) |
| Net cash used in operating activities | (11,011,840) | (12,886,874) |
| Investing activities | ||
| Purchases of short-term investments | — | (1,473,419) |
| Maturities of short-term investments | — | 4,500,000 |
| Proceeds from the disposal of fixed assets | — | 7,500 |
| Purchases of property and equipment | (120,197) | (384,117) |
| Net cash (used in) provided by investing activities | (120,197) | 2,649,964 |
| Financing activities | ||
| Proceeds from issuance of common stock in connection with private placement | 836,777 | 6,037,500 |
| Proceeds from issuance of warrants in connection with private placement | 1,813,223 | — |
| Proceeds from issuance of common stock in connection with at-the-market offering program | 5,033,906 | 2,552,656 |
| Issuance costs attributed to common stock and warrants issued in private placement | (1,320) | (836,938) |
| Issuance costs in connection with at-the-market offering program | (236,597) | (234,725) |
| Deferred issuance costs in connection with at-the-market offering program | (20,000) | — |
| Deferred issuance costs in connection with debt facility | (75,000) | — |
| Share repurchases for the payment of employee taxes | (81,403) | (119,419) |
| Net cash provided by financing activities | 7,269,586 | 7,399,074 |
| Net decrease in cash and cash equivalents | (3,862,451) | (2,837,836) |
| Cash and cash equivalents at beginning of year | 5,322,493 | 8,160,329 |
| Cash and cash equivalents at end of year | $1,460,042 | $5,322,493 |
| Supplemental non-cash financing and investing transactions: | ||
| Unpaid purchases of property and equipment | $— | $4,631 |
| Modification of right-of-use asset and associated lease liability | $199,385 | $97,536 |
| Non-cash warrants issued in connection with debt facility | $53,124 | $— |
| Unpaid issuance costs in connection with private placement | $185,903 | $— |
| Unpaid deferred issuance costs | $95,837 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.